Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: evaluation report and supporting information

Table of contents

01 - Pre-meeting Briefing

02 - Submission from the technology manufacturer – Novartis

03 - NICE request to the manufacturer for clarification on their submission

04 - Company clarification response

05 - Consultee submission - Allergy UK

06 - Consultee submission - British Association of Dermatologists

07 - Consultee submission - British Society for Allergy and Clinical Immunology

08 - Consultee submission - Royal College of Pathologists

09 - Consultee submission - Royal College of Physicians

10 - Consultee submission - Dermatology Clinical Reference Group (CRG) for Specialised Commissioning, NHS England

11 - Clinical expert personal perspective - Dr Clive Grattan

12 - Patient expert personal perspective - Maureen Jenkins

13 - Clinical expert personal perspective - Dr Shuaib Nasser

14 - Patient expert personal perspective - Deborah Shipman

15 - Clinical expert personal perspective - Dr Sinisa Savic

16 - Evidence Review Group report prepared by Southampton Health Technology Assessments Centre

17 - Erratum to Evidence Review Group report

18 - Evidence Review Group response to the company's factual accuracy check

 

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 13 November 2014